Study #2020-0353
Bone loss in cancer survivors receiving adjuvant immune checkpoint inhibitor therapy
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
This study investigates the bone-related side effects caused by immunotherapy drugs such as nivolumab and pembrolizumab in patients with melanoma. Nivolumab and pembrolizumab are immunotherapy drugs (drugs that boost your immune system) used to prevent cancer from coming back in patients with melanoma. Specifically, researchers want to learn if there is any relationship between receiving immunotherapy and bone density (thickness) measured by a dual-energy X-ray absorptiometry (DXA) scan or bone turnover markers (which indicate levels of bone loss) found in the blood. This study may provide researchers with more information on bone loss and may help prevent bone loss in future patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Clinical Stage III Cutaneous Melanoma AJCC v8;Clinical Stage IV Cutaneous Melanoma AJCC v8;Pathologic Stage III Cutaneous Melanoma AJCC v8;Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;Pathologic Stage IIID Cutaneous Melanoma AJCC v8;Pathologic Stage IV Cutaneous Melanoma AJCC v8
Study phase:
Physician name:
Noha Hassan
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-844-936-2191
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.